Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Galectin Therapeutics, Inc. (GALT) Starts Presentation at LD Micro Conference

Galectin Therapeutics is a clinical stage biopharmaceutical company that is focused on research and development of therapies for fibrotic disease and cancer. The company’s lead product candidates are GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a phase 1/2 clinical trials in Belgium as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer.  For more information, visit the company’s website at

The three-day LD Micro Invitational in Bel Air, California, features company presentations from more than 200 select high-potential small-cap companies spanning multiple industries. Institutional and retail investors in attendance also have access to numerous networking opportunities and social events to learn more about these companies. For more information on LD Micro, visit
This entry was posted in LD Micro Conference. Bookmark the permalink.

Comments are closed.